Abstract The β-amyloid radiotracer 18FNAV4694 is a desirable alternative to 11CPiB, possessing similar imaging characteristics and favorable radiopharmaceutical distribution. This work examined the consistency of amyloid measures between 11CPiB and 18FNAV4694 as participants transition between radiotracers in longitudinal studies. Thirty-five participants with ≥1 11CPiB scans, followed by a 18FNAV4694 scan, were recruited from ongoing AD studies at the University of Wisconsin. Amyloid stability was evaluated in Aβ- individuals and amyloid accumulation was evaluated in Aβ+ individuals. In Aβ- participants, 18FNAV4694 measures were consistent with the preceding 11CPiB measures, showing no significant differences in CL values. Aβ+ participants exhibited an average annualized Aβ accumulation of 6.0 ± 1.8 CL/yr, consistent with modeled 11CPiB Aβ projected outcomes. 18FNAV4694 demonstrated both consistency in trending amyloid accumulation and constancy in sustained Aβ- participants compared to 11CPiB. This study highlights how both radiotracers can be integrated within a single analytical framework under a uniform processing pipeline.
Bettcher et al. (Thu,) studied this question.